Related Experiment Video

Updated: Jun 16, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Management of patients with advanced non-small cell lung cancer: current and emerging options

Laura R Triano1, Hari Deshpande, Scott N Gettinger

  • 1Yale Cancer Center/Yale University School of Medicine, New Haven, Connecticut, USA.

Drugs
|January 30, 2010
PubMed

Insights

Systemic therapy for advanced non-small cell lung cancer (NSCLC) is shifting towards molecularly targeted agents. Erlotinib, bevacizumab, and cetuximab show improved survival, paving the way for personalized NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Traditional chemotherapy for advanced non-small cell lung cancer (NSCLC) has reached a plateau in improving patient outcomes.
  • Recent advancements focus on molecularly targeted agents to enhance quality of life and overall survival in NSCLC patients.

Purpose of the Study:

  • To review the evolution of systemic therapy for advanced non-small cell lung cancer (NSCLC).
  • To highlight the impact of molecularly targeted agents on survival and the future direction of personalized NSCLC treatment.

Main Methods:

  • Review of clinical trials and FDA approvals for systemic therapies in advanced NSCLC.
  • Analysis of data on erlotinib, bevacizumab, and cetuximab efficacy.
  • Discussion of ongoing research into predictive biomarkers for individualized therapy.

Main Results:

  • Erlotinib (EGFR inhibitor) and bevacizumab (anti-VEGF antibody) have demonstrated improved overall survival in advanced NSCLC.
  • Cetuximab (EGFR antibody) also shows promising results when combined with chemotherapy.
  • Ongoing trials are evaluating additional targeted agents and predictive markers.

Conclusions:

  • Molecularly targeted agents represent a significant advancement in the systemic therapy of advanced NSCLC.
  • Personalized treatment strategies based on predictive clinical and molecular characteristics are the future of NSCLC management.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...